Please provide your email address to receive an email when new articles are posted on . A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ...
PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...
DSG3-CAART is designed to selectively target the cause of mucosal pemphigus vulgaris. The Food and Drug Administration (FDA) has granted Fast Track designation to DSG3-CAART (desmoglein 3 chimeric ...
Please provide your email address to receive an email when new articles are posted on . Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been ...
The approval was based on data from the Ritux 3 trial (N=90) which compared rituximab + short-term oral prednisone (Ritux 3 regimen) to oral prednisone alone as a first-line treatment for patients ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Significantly ...
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy for patients with autoimmune diseases where B cells contribute to the initiation and/or maintenance of disease.
PHILADELPHIA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The conventional treatment mainstays for pemphigus are problematic during the COVID-19 pandemic, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, today announced that PRN1008, a reversible covalent Bruton’s Tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback